

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

---

**SCHEDULE 14A**

**Proxy Statement Pursuant to Section 14(a) of  
the Securities Exchange Act of 1934 (Amendment No. )**

---

Filed by the Registrant   
Filed by a Party other than the Registrant

Check the appropriate box:

- Preliminary Proxy Statement  
 **Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))**  
 Definitive Proxy Statement  
 Definitive Additional Materials  
 Soliciting Material under §240.14a-12



**DECIPHERA PHARMACEUTICALS, INC.**

---

(Name of Registrant as Specified In Its Charter)

---

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

- No fee required.  
 Fee paid previously with preliminary materials.  
 Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.



P.O. BOX 8016, CARY, NC 27512-9903

## Deciphera Pharmaceuticals, Inc. Important Notice Regarding the Availability of Proxy Materials

**Stockholders Meeting to be held on  
June 21, 2023**

**For Stockholders of record as of April 24, 2023**

This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting.

To view the proxy materials, and to obtain directions to attend the meeting, go to: [www.proxydocs.com/DCPH](http://www.proxydocs.com/DCPH)

To vote your proxy while visiting this site, you will need the 12 digit control number in the box below.

Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the internet.



**For a convenient way to view proxy materials and VOTE go to  
[www.proxydocs.com/DCPH](http://www.proxydocs.com/DCPH)**

**Have the 12 digit control number located in the shaded box above available  
when you access the website and follow the instructions.**

*If you want to receive a paper or e-mail copy of the proxy material, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year's meeting, you must make this request on or before June 09, 2023.*

**To order paper materials, use one of the following methods.**

  
**INTERNET**  
[www.investorelections.com/DCPH](http://www.investorelections.com/DCPH)

  
**TELEPHONE**  
**(866) 648-8133**

  
**\* E-MAIL**  
[paper@investorelections.com](mailto:paper@investorelections.com)

When requesting via the Internet or telephone you will need the 12 digit control number located in the shaded box above.

\* If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located above) in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting material.

### Deciphera Pharmaceuticals, Inc.

**Meeting Type:** Annual Meeting of Stockholders  
**Date:** Wednesday, June 21, 2023  
**Time:** 8:30 AM, Eastern Time  
**Place:** Annual Meeting to be held live via the Internet - please visit [www.proxydocs.com/DCPH](http://www.proxydocs.com/DCPH) for more details.

**You must register to attend the meeting online and/or participate at [www.proxydocs.com/DCPH](http://www.proxydocs.com/DCPH)**

**SEE REVERSE FOR FULL AGENDA**

# Deciphera Pharmaceuticals, Inc.

## Annual Meeting of Stockholders

**THE BOARD OF DIRECTORS RECOMMENDS A VOTE:  
FOR ON PROPOSALS 1, 2 AND 3**

**PROPOSAL**

1. To elect three Class III directors, as nominated by the Board of Directors, to hold office until the 2026 Annual Meeting of Stockholders or until their successors are duly elected and qualified or until their earlier death, resignation, or removal;
  - 1.01 Patricia L. Allen
  - 1.02 Edward J. Benz, Jr., M.D.
  - 1.03 Dennis L. Walsh
2. To approve, on a non-binding, advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement accompanying this notice;
3. To ratify the appointment of PricewaterhouseCoopers LLP as Deciphera Pharmaceuticals, Inc.'s independent registered public accounting firm for the year ending December 31, 2023;
4. To transact such other business as may properly come before the meeting and at any adjournments or postponements thereof.